methyl 3-methoxy-5-(trifluoromethanesulfonyloxy)benzoate | 916343-75-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 3-methoxy-5-(trifluoromethanesulfonyloxy)benzoate
• 英文别名: 3-methoxy-5-trifluoromethanesulfonyloxy-benzoic acid methyl ester；methyl 3-methoxy-5-(tetrazol-5-yl)benzoate；Methyl 3-methoxy-5-trifluoromethanesulfonyloxybenzoate；methyl 3-methoxy-5-(trifluoromethylsulfonyloxy)benzoate
• CAS: 916343-75-4
• 化学式: C₁₀H₉F₃O₆S
• 分子量: 314.239
• InChiKey: XUOFOSUUEVSWML-UHFFFAOYSA-N

物化性质

• 沸点：
  371.3±42.0 °C(Predicted)
• 密度：
  1.477±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  87.3
• 氢给体数：
  0
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  methyl 3-methoxy-5-(trifluoromethanesulfonyloxy)benzoate 在 sodium periodate 、 PdCl2(dppf)*CHCl3 、 ammonium acetate 、 potassium acetate 作用下， 以 1,4-二氧六环 、 水 、 丙酮 为溶剂， 生成 3-甲氧基-5-甲氧酰基苯硼酸
  参考文献：
  名称：

  Discovery of a Novel Series of Benzoic Acid Derivatives as Potent and Selective Human β₃ Adrenergic Receptor Agonists with Good Oral Bioavailability. 3. Phenylethanolaminotetraline (PEAT) Skeleton Containing Biphenyl or Biphenyl Ether Moiety

  摘要：

  We designed a series of benzoic acid derivatives containing the biphenyl ether or biphenyl template on the RHS and a phenylethanolaminotetraline (PEAT) skeleton, which was prepared by highly stereoselective synthesis, to generate two structurally different lead compounds (10c, 10m) with a good balance of potency, selectivity, and pharmacokinetic profile. Further optimization of the two lead compounds to improve potency led to several potential candidates (i.e., 11f, 11l, 11o, 12b). In particular, biphenyl analogue 12b exhibited an excellent balance of high potency (EC(50) = 0.38 nM) for beta(3), high selectivity over beta(1) and beta(2), and good pharmacokinetic properties in rats, dogs, and monkeys.

  DOI：

  10.1021/jm800222k
• 作为产物：
  描述：

  methyl 3-hydroxy-5-trifluoromethane-sulfonyloxybenzoate 、 碘甲烷 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 17.0h， 生成 methyl 3-methoxy-5-(trifluoromethanesulfonyloxy)benzoate
  参考文献：
  名称：

  WO2008/88692

  摘要：

  公开号：

文献信息

• Amide derivatives as somatostatin receptor 5 antagonists
  申请人：Binggeli Alfred

  公开号：US20060276508A1

  公开（公告）日：2006-12-07

  This invention is concerned with compounds of the formula wherein R 1 to R 5 , R 5′ and A are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

  这项发明涉及以下式中的化合物，其中R1至R5、R5'和A如描述和索赔中所定义，并且其药学上可接受的盐。该发明还涉及含有这种化合物的药物组合物，以及用于治疗和/或预防与调节SST受体亚型5相关的疾病的方法。
• SPIROCHROMANON DERIVATIVES
  申请人：Iino Tomoharu

  公开号：US20090270436A1

  公开（公告）日：2009-10-29

  The invention relates to a compound of a general formula (I): wherein Ar1 represents a group formed from an aromatic ring selected from a group consisting of benzene, pyrazole, isoxazole, pyridine, indole, 1H-indazole, 1H-furo[2,3-c]pyrazole, 1H-thieno[2,3-c]pyrazole, benzimidazole, 1,2-benzisoxazole, imidazo[1,2-a]pyridine, imidazo[1,5-a]pyridine and 1H-pyrazolo[3,4-b]pyridine, having Ar2, and optionally having one or two or more substituents selected from R3: R1 and R2 each independently represent a hydrogen atom, a halogen atom, a cyano group, a C2-C6 alkenyl group, a C1-C6 alkoxy group, a C2-C7 alkanoyl group, a C2-C7 alkoxycarbonyl group, an aralkyloxycarbonyl group, a carbamoyl-C1-C6 alkoxy group, a carboxy-C2-C6 alkenyl group, or a group of -Q1-N(Ra)-Q2-Rb; or a C1-C6 alkyl group optionally having a substituent; or an aryl or heterocyclic group optionally having a substituent; or a C1-C6 alkyl group or a C2-C6 alkenyl group having the aryl or heterocyclic group; T and U each independently represent a nitrogen atom or a machine group; and V represents an oxygen atom or a sulfur atom. The compound of the invention is useful as therapeutical agents for various ACC-related diseases.

  本发明涉及一种通式（I）的化合物：其中Ar1代表从苯，吡唑，异噁唑，吡啶，吲哚，1H-吲唑，1H-呋喃[2,3-c]吡唑，1H-噻吩[2,3-c]吡唑，苯并咪唑，1,2-苯并异噁唑，咪唑并[1,2-a]吡啶，咪唑并[1,5-a]吡啶和1H-吡唑并[3,4-b]吡啶中选择的芳香环形成的基团，具有Ar2，并且可选地具有一个、两个或更多从R3中选择的取代基：R1和R2各自独立地表示氢原子，卤素原子，氰基，C2-C6烯基基团，C1-C6烷氧基团，C2-C7烷酰基基团，C2-C7烷氧羰基基团，芳基烷氧羰基基团，氨基-C1-C6烷氧基团，羧基-C2-C6烯基基团或-Q1-N（Ra）-Q2-Rb基团；或者是一个可选具有取代基的C1-C6烷基基团；或者是一个可选具有取代基的芳基或杂环基团；或者是一个具有芳基或杂环基团的C1-C6烷基或C2-C6烯基基团；T和U各自独立地表示氮原子或机器基团；V表示氧原子或硫原子。本发明的化合物可用作治疗各种ACC相关疾病的治疗剂。
• Spirochromanon derivatives
  申请人：MSD K.K.

  公开号：US08138197B2

  公开（公告）日：2012-03-20

  The invention relates to a compound of a general formula (I): wherein Ar1 represents a group formed from an aromatic ring selected from a group consisting of benzene, pyrazole, isoxazole, pyridine, indole, 1H-indazole, 1H-furo[2,3-c]pyrazole, 1H-thieno[2,3-c]pyrazole, benzimidazole, 1,2-benzisoxazole, imidazo[1,2-a]pyridine, imidazo[1,5-a]pyridine and 1H-pyrazolo[3,4-a]pyridine, having Ar2, and optionally having one or two or more substituents selected from R3; R1 and R2 each independently represent a hydrogen atom, a halogen atom, a cyano group, a C2-C6 alkenyl group, a C1-C6 alkoxy group, a C2-C7 alkanoyl group, a C2-C7 alkoxycarbonyl group, an aralkyloxycarbonyl group, a carbamoyl-C1-C6 alkoxy group, a carboxy-C2-C6 alkenyl group, or a group of -Q1-N(Ra)-Q2-Rb; or a C1-C6 alkyl group optionally having a substituent; or an aryl or heterocyclic group optionally having a substituent; or a C1-C6 alkyl group or a C2-C6 alkenyl group having the aryl or heterocyclic group; T and U each independently represent a nitrogen atom or a methine group; and V represents an oxygen atom or a sulfur atom. The compound of the invention is useful as therapeutical agents for various ACC-related diseases.

  本发明涉及一种通式(I)的化合物： 其中Ar1代表由苯、吡唑、异氧唑、吡啶、吲哚、1H-吲唑、1H-呋喃[2,3-c]吡唑、1H-噻吩[2,3-c]吡唑、苯并咪唑、1,2-苯并异氧唑、咪唑并[1,2-a]吡啶、咪唑并[1,5-a]吡啶和1H-吡唑并[3,4-a]吡啶中选取的芳香环组成的基团，具有Ar2，并可选地具有一个或两个或更多的取代基，所述取代基选自R3；R1和R2各自独立地代表氢原子、卤素原子、氰基、C2-C6烯基基团、C1-C6烷氧基团、C2-C7烷酰基基团、C2-C7烷氧羰基基团、芳基烷氧羰基基团、氨基-C1-C6烷氧基团、羧基-C2-C6烯基基团，或-Q1-N(Ra)-Q2-Rb的基团；或者是具有取代基的C1-C6烷基基团；或者是具有取代基的芳基或杂环基团；或者是具有芳基或杂环基团的C1-C6烷基或C2-C6烯基基团；T和U各自独立地代表氮原子或甲基基团；V代表氧原子或硫原子。本发明的化合物可用作治疗各种与ACC相关的疾病的治疗剂。
• Rational design of inhibitors of the bacterial cell wall synthetic enzyme GlmU using virtual screening and lead-hopping
  作者：Peter Doig、P. Ann Boriack-Sjodin、Jacques Dumas、Jun Hu、Kenji Itoh、Kenneth Johnson、Steven Kazmirski、Tomohiko Kinoshita、Satoru Kuroda、Tomo-o Sato、Kaori Sugimoto、Katsumi Tohyama、Hiroshi Aoi、Kazusa Wakamatsu、Hongming Wang

  DOI：10.1016/j.bmc.2014.08.017

  日期：2014.11

  An aminoquinazoline series targeting the essential bacterial enzyme GlmU (uridyltransferase) were previously reported (Biochem. J. 2012, 446, 405). In this study, we further explored SAR through a combination of traditional medicinal chemistry and structure-based drug design, resulting in a novel scaffold (benzamide) with selectivity against protein kinases. Virtual screening identified fragments that could be fused into the core scaffold, exploiting additional binding interactions and thus improving potency. These efforts resulted in a hybrid compound with target potency increased by a 1000-fold, while maintaining selectivity against selected protein kinases and an improved level of solubility and protein binding. Despite these significant improvements no significant antibacterial activity was yet observed within this class. (C) 2014 Elsevier Ltd. All rights reserved.
• Targeting the Heat Shock Protein 90 Dimer with Dimeric Inhibitors
  作者：Bhaskar Reddy Kusuma、Laura B. Peterson、Huiping Zhao、George Vielhauer、Jeffrey Holzbeierlein、Brian S. J. Blagg

  DOI：10.1021/jm200553w

  日期：2011.9.22

  The design, synthesis, and biological evaluation of conformationally constrained coumermycin Al analogues are reported. Compounds were evaluated against both breast cancer (SKBr3 and MCF7) and prostate cancer (PC3 mm2, A549, and HT29) cell lines. Non-noviosylated coumermycin Al analogues that manifest potent antiproliferative activity resulting from Hsp90 inhibition are provided, wherein replacement of the stereochemically complex noviose sugar with readily available piperidine rings resulted in similar to 100 fold increase in antiproliferative activities as compared to coumermycin Al, producing small molecule Hsp90 inhibitors that exhibit nanomolar activities.